Cell-free DNA could be the next big breakthrough in detecting gastrointestinal cancers, according to Brian M. Wolpin, MD, MPH, director of the Gastrointestinal Cancer Center, and director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer.
Cell-free DNA could be the next big breakthrough in detecting gastrointestinal cancers, according to Brian M. Wolpin, MD, MPH, director of the Gastrointestinal Cancer Center, and director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer.
Wolpin recently discussed findings from the Circulating Cell-Free Genome Atlas (CCGA) study (NCT02889978).
Transcription
Using circulating cell-free DNA, and in particular a targeted methylation approach, which is what we've done in this study, can detect cancers with good sensitivity and with very high specificity. The high specificity is really important because it reduces the number of false positive tests that would occur where you start to screen people in the general population. The sensitivity is important because that's what allows you to identify patients early, before the disease has become advanced.
The main takeaway is that cell-free DNA testing can allow gastrointestinal tumor detection with high sensitivity and high specificity. And it also allowed us to try to identify the site of origin of the cancer, meaning which organ did it originate from. We were able to do that with approximately 90% accuracy.
Oncology Nurses Provide Patients an Avenue to Supportive Care
November 12th 2019Palliative care is often associated with a patient entering end of life treatment and giving up on their treatment, but that isn't the reality of what id can do for patients. And oncology nurses can help guide patients to the right supportive care for them.
Hyman B. Muss Discusses the Importance of Nurses in Treating Pregnant Women With Breast Cancer
March 23rd 2016Hyman B. Muss, MD, professor of medicine at the University of North Carolina School of Medicine, discusses the vital roles that nurses play when it comes to treating pregnant women with breast cancer.
Kimberly J. Van Zee on Nomograms Helping in DCIS Treatment Decision-Making
March 18th 2016Kimberly J. Van Zee, MS, MD, FACS, attending surgeon at Memorial Sloan Kettering Cancer Center, discusses the institution's newly-developed nomogram that can help women make treatment decisions about ductal carcinoma in situ (DCIS).